REG - IXICO plc - Validation of Neuroimaging Technology Platform

IXICOAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260226:nRSZ4387Ua&default-theme=true

RNS Number : 4387U  IXICO plc  26 February 2026

IXICO plc

("IXICO", the "Company" or the "Group")

IXICO further validates the automation capabilities of

its IXI™ neuroimaging technology platform

 

 

26 February 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader
in neuroscience imaging and biomarker analytics, using its AI-driven platform
to help advance drug development in neurological disorders, announced it has
presented new data demonstrating that automated capabilities to measure brain
volume loss on magnetic resonance imaging (MRI) within its IXI™ Platform are
at a minimum matching, and in some measures exceeding, the performance of
semi-manual methods which require manual analysis by (human) experts.

 

The accurate measurement of brain volume shrinkage (brain atrophy), caused
by the loss of brain cells and the breakdown of connections between them, is
fundamental to developing new treatments for a number of neurodegenerative
diseases, including Huntington's Disease (HD).  Traditionally, researchers
have relied on a semi-manual approach to measure brain volume loss, known as
the Boundary Shift Integral (BSI) which is currently considered to be the
'gold standard' method of analysis.

 

In a recent study conducted by IXICO and a large US pharmaceutical partner,
the results show that automated capabilities to measure brain atrophy on MRI
 within its IXI™ Platform match or exceed the performance
of the semi-manual BSI method, providing an advanced, cost-effective and
scalable solution to support clinical trials in HD.  Of the three approaches
evaluated to measure brain atrophy, IXI™ demonstrated it was the most
sensitive method for detecting whole brain and caudate (a small region deep in
the brain impacted early in HD) volume loss.

 

A full summary of the study and more detail on the data presented is available
on IXICO's website by following this link
(https://ixico.com/news-and-resources/publications/further-validation-of-ixi-technology-platform-automation-capabilities)
.   The data is being presented in a scientific poster at the 21(st) Annual
Huntington's Disease Therapeutics Conference in California, USA this week
(23-26 February 2026).

 

Robin Wolz, Chief Scientific Officer of IXICO, commented: "By using a
scalable, sensitive AI imaging analysis approach such as on our IXI(TM)
Platform, researchers can reduce the operational burden of semi-manually
analysed images and increase sensitivity to detecting changes in the brain.
It is my belief that this has huge potential to impact how biomarker analyses
inform the next generation of drug development programs in neurodegenerative
disease".

 

Ends

 

For further information please contact:

 

 IXICO plc                                        +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited                +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny, Isaac Hooper (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKELFLQLLXBBV



            Copyright 2019 Regulatory News Service, all rights reserved